Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2020

View Archived Issues

Homology initiates IND-enabling studies of novel gene therapy for Hunter syndrome

Feasibility trial of preoperative ipilimumab/nivolumab in locoregionally advanced urothelial cancer

Enrollment ongoing in phase I study of ALN-HSD

IAVI, Merck KGaA and Serum Institute of India collaborate to develop MAbs for COVID-19

Immutep announces investigator-initiated study of eftilagimod alpha in patients with COVID-19

Evgen Pharma receives all approvals to initiate STAR trial of SFX-01

Ultragenyx and Solid Biosciences collaborate to develop new gene therapies for DMD

First patient dosed in phase Ib/II study of dubermatinib plus decitabine in AML

Preclinical data presented for UB-612 vaccine against COVID-19

University of Central Florida patents new antimalarials

Janssen Pharmaceutica patent describes FFAR4 agonists

Anadolu Ueniversitesi discloses new compounds for cancer

Venenum Biodesign synthesizes TREX1 inhibitors

PhaseBio discontinues VANGARD study of pemziviptadil in patients with COVID-19

Hangzhou Sumgen Biotechnology discloses new fusion proteins for cancer immunotherapy

Phase III study of BiondVax's universal flu vaccine candidate M-001 does not meet primary endpoint

Targeting liver repair with an RSPO mimetic

LIDDS' NZ-TLR9 demonstrates antitumoral effect in mouse tumor models

KRAS G12C: Adagrasib holds its own at ENA 2020

Anelixis begins phase IIa study of AT-1501 in ALS

IDMC recommends continuation of phase III trial of REX-001 for diabetic CLI

Subcutaneous lirentelimab demonstrates sustained eosinophil suppression in phase I trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...